ʻO Seelos Therapeutics, Inc., kahi hui biopharmaceutical clinical-stage i kālele ʻia i ka hoʻomohala ʻana i nā lāʻau lapaʻau no nā maʻi o ka ʻōnaehana nerve waena a me nā maʻi laha ʻole, i kēia lā ua hoʻolaha ʻia ua loaʻa iā ia kahi leka hoʻomaopopo o kahi Clinical Trial Notification (CTN) mai ka Australian Government Department of Health. Therapeutic Goods Administration (TGA) no kahi noiʻi pailaka o SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) no ka mālama ʻana i nā maʻi me ka maʻi o Alzheimer.
"He mea kū hoʻokahi ka hana a Trehalose i ka maʻi o Alzheimer no ka mea e pale ana i ka pathology beta-amyloid a me nā hui tau i nā kumu hoʻohālike preclinical rodent. ʻIke ʻia kēia hana he intraneuronal, e kū ana i loko o ke kelepona, ʻokoʻa ia mai nā lāʻau lapaʻau e pili ana i ka antibody. He cytoplasmic ʻelua ʻelua amyloid precursor protein a me tau oligomers i loko o ke kelepona a hiki ke hana ʻia e Trehalose ma ka hoʻoulu ʻana i nā ʻōnaehana autophagy a me proteasomal. Ua hoʻopili ʻia ʻo Autophagy i ka hoʻohaʻahaʻa ʻana i nā ʻāpana protein ʻē aʻe i kuhi hewa ʻia, "wahi a Raj Mehra Ph.D., Luna Hoʻokele a me Luna Nui o Seelos. "Ke manaʻo nei mākou e loaʻa nā hōʻike a me nā ʻike koʻikoʻi i ke kūpono o SLS-005 i ka mālama ʻana i kēia mau maʻi neurological, he mea hōʻino loa i ke kino, ka naʻau a me ke kālā i nā maʻi a me ko lākou ʻohana."
Eia kekahi, ua loaʻa iā Seelos ka ʻae e hana i kahi haʻawina hīnaʻi wehe ʻokoʻa (ACTRN: 12621001755820) ma Australia e loiloi i ka maikaʻi o SLS-005 i ka piʻi ʻana o ka maʻi a me ka paʻakikī, a me kona palekana a me ka hoʻomanawanui, i nā poʻe komo me nā maʻi neurodegenerative i koho ʻia. me ka ma'i o Huntington.
ʻO ke kino hoʻoponopono o Australia no nā hoʻokolohua lapaʻau, ka TGA, a me ka Australian Government's Research and Development Tax Incentive e hāʻawi i kahi manawa maikaʻi loa no nā hui biotech liʻiliʻi o US e hoʻomaka i nā hoʻokolohua lapaʻau ma Australia i ka hoʻāʻo ʻana e wikiwiki i ka hoʻomaka ʻana o nā haʻawina a hoʻohana i ka lāʻau lapaʻau ikaika o ka ʻāina. nā mana hoʻāʻo.
He aha e lawe ʻia mai kēia ʻatikala:
- ʻO ke kino hoʻoponopono o Australia no nā hoʻokolohua lapaʻau, ka TGA, a me ka Australian Government's Research and Development Tax Incentive e hāʻawi i kahi manawa maikaʻi loa no nā hui biotech liʻiliʻi o US e hoʻomaka i nā hoʻokolohua lapaʻau ma Australia i ka hoʻāʻo ʻana e wikiwiki i ka hoʻomaka ʻana o nā haʻawina a hoʻohana i ka lāʻau lapaʻau ikaika o ka ʻāina. nā mana hoʻāʻo.
- , he hui biopharmaceutical clinical-stage e kālele ana i ka hoʻomohala ʻana i nā lāʻau lapaʻau no nā maʻi o ka ʻōnaehana nerve waena a me nā maʻi laha ʻole, i kēia lā ua hoʻolaha ʻia ua loaʻa iā ia kahi leka hoʻomaopopo o kahi Clinical Trial Notification (CTN) mai ka Australian Government Department of Health Therapeutic Goods Administration (TGA). ) no ka noiʻi pailaka o SLS-005 (trehalose injection, 90.
- 12621001755820) ma Australia e loiloi i ka pono o SLS-005 i ka holomua o ka maʻi a me ka paʻakikī, a me kona palekana a me ka hoʻomanawanui ʻana, i nā poʻe komo me nā maʻi neurodegenerative i koho ʻia me ka maʻi o Huntington.
